The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response

Key words: chronic myeloid leukemia, BCR-ABL expression, automated GeneXpert method

chronic myeloid leukemia, BCR-ABL expression, automated GeneXpert method

1. Baccarani M., Deininger M.W., Rosti G. et al. European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia: 2013. Blood 2013;122(6):872–84.

2. Куцев С.И. Эволюция мониторинга лечения хронического миелоидного лейкоза. Гематол и трансфузиол 2009;54(4):36–44.

3. Hughes T., Deininger M., Hochhaus A. et al. Monitoring CML patients responding to treatment with yrosine kinase inhibitors – review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.

4. Mueller M., Cross N., Erben P. et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009;23:1957–63.

5. Дубина М.В., Куевда Д.А., Хомякова Т.Е. и др. Молекулярный мониторинг эффективности терапии больных хроническим миелолейкозом в России. Совр онкол 2010;12(4):11–7.

6. Zaritskey A., Bobrynina V., Tsaur G. et al. International Standardization of qualitative studies of BCR-ABL chronic myeloid leukemia patients in Russia. Haematologica 2012;97(Suppl 1):545.

7. Hughes T., Kaeda J., Branford S. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–32.

8. Cross N., White H., Mueller M. et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172–5.

9. Müller M.C., Munjal U., Erben P. et al. Stability of Conversion Factors for BCR-ABL Monitoring – Implications for the Frequency of Validation Rounds. Blood 2010;116:893.

10. Raja S., Ching J., Xi L. et al. Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem 2005;51:882–90.

11. Cayuela J.-M., Macintyre E., Darlington M. et al. Cartridge-based automated BCRABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica 2011;96:664–71.

12. López-Jorge C., Gómez-Casares M., Jiménez-Velasco A. et al. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Ann Hemat 2012;91:1245–50.

13. Sacha T., Zawada M., Leszczyńska A. et al. Comparison of the BCR-ABL gene expression

14. analysis by the GeneXpert System and standardized RQ-PCR method in three Polish Molecular Laboratories in patients with chronic phase chronic myeloid leukemia treated with TKIs. Haematologica 2012;97(Suppl 1):286.

15. Winn-Deen E.S., Helton B., Van Atta R. et al. Development of an integrated assay for detection of BCR-ABL RNA. Clinical chemistry 2007;53(9):1593–1600.

16. Altman D., Bland J. Measurement in Medicine: the Analysis of Method Comparison Studies. The Statistician 1983;32:307–17.

17. Jobbagy Z., van Atta R., Murphy K.M. et al. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diag 2007;9(2): 220–7.

18. Dufresne S.D., Belloni D.R., Levy N.B., Tsongalis G.J. Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay. Arch Pathol Lab Med 2007;131(6):947–50.

19. Туркина А.Г., Челышева Е.Ю. Стратегия терапии хронического миелолейкоза: возможности и перспективы. Тер архив 2013;7:4–9.